Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Current Liabilities: 2016-2024

Historic Total Current Liabilities for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $45.9 million.

  • UroGen Pharma's Total Current Liabilities rose 28.84% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 28.84%. This contributed to the annual value of $45.9 million for FY2024, which is 47.22% up from last year.
  • UroGen Pharma's Total Current Liabilities amounted to $45.9 million in FY2024, which was up 47.22% from $31.2 million recorded in FY2023.
  • UroGen Pharma's 5-year Total Current Liabilities high stood at $45.9 million for FY2024, and its period low was $21.4 million during FY2020.
  • Its 3-year average for Total Current Liabilities is $33.7 million, with a median of $31.2 million in 2023.
  • Data for UroGen Pharma's Total Current Liabilities shows a peak YoY spiked of 47.22% (in 2024) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Total Current Liabilities (Yearly) stood at $21.4 million in 2020, then grew by 4.40% to $22.4 million in 2021, then climbed by 6.86% to $23.9 million in 2022, then skyrocketed by 30.51% to $31.2 million in 2023, then spiked by 47.22% to $45.9 million in 2024.